As of Apr 29
| +0.01 / +0.27%|
The 2 analysts offering 12-month price forecasts for PDL BioPharma Inc have a median target of 4.00, with a high estimate of 4.00 and a low estimate of 4.00. The median estimate represents a +6.10% increase from the last price of 3.77.
The current consensus among 2 polled investment analysts is to Hold stock in PDL BioPharma Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.